Prognostic impact and gene expression analysis of peri-tumoral alveolar macrophage in resected lung adenocarcinoma.


Journal

Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776

Informations de publication

Date de publication:
Aug 2023
Historique:
revised: 21 04 2023
received: 19 12 2022
accepted: 26 04 2023
medline: 3 8 2023
pubmed: 2 6 2023
entrez: 2 6 2023
Statut: ppublish

Résumé

The prognostic significance and role of extratumoral alveolar macrophages (exAMs) in lung adenocarcinoma (LUAD) patients remain unknown. In this study, we investigated the prognostic impact and gene expression of exAMs in LUAD patients. The density of alveolar macrophages (AMs) in the peri-tumoral lung field (p-exAMs) and distant lung field (d-exAMs) was evaluated in 217 LUAD patients with lymph node metastasis. Patients with high p-exAMs showed significantly shorter recurrence-free (RFS) and shorter overall survival (OS) than those with low p-exAMs (p = 0.02 and p = 0.03, respectively), whereas there was no survival difference between patients with high d-exAMs and those with low d-exAMs. Multivariate analysis revealed that high p-exAMs was an independent predictive factor for RFS (HR: 1.54; 95% confidence interval [CI]:1.10-2.16; p = 0.01). Later, we collected AMs from the tumor periphery and distant segments in 13 resected lungs by bronchoalveolar lavage (BAL) procedure and compared mRNA expression. AMs in the tumor periphery expressed significantly higher levels of IL-10 and CCL2 than those in the distant segment (p < 0.01 and p = 0.03, respectively). Additionally, IL-10 and CCL2 significantly induced the growth and migration of the PC9 cells in vitro. This study suggests that p-exAMs should be considered as a tumor-promoting component in the tumor microenvironment.

Identifiants

pubmed: 37264761
doi: 10.1111/cas.15848
pmc: PMC10394127
doi:

Substances chimiques

Interleukin-10 130068-27-8

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3423-3432

Subventions

Organisme : Japan Society for the Promotion of Science
ID : 21H02931
Organisme : National Cancer Center Japan
ID : 2020-A-9

Informations de copyright

© 2023 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Références

Science. 2014 May 23;344(6186):921-5
pubmed: 24812208
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
J Thorac Oncol. 2010 Oct;5(10):1507-15
pubmed: 20802348
Cell Biol Int. 2017 Sep;41(9):960-968
pubmed: 28493530
Lung Cancer. 2018 Sep;123:127-135
pubmed: 30089583
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Cancer Cell. 2012 Mar 20;21(3):309-22
pubmed: 22439926
Cancer Sci. 2023 Aug;114(8):3423-3432
pubmed: 37264761
Br J Cancer. 1998 May;77(10):1696-703
pubmed: 9635852
Int J Cancer. 2019 Aug 15;145(4):1099-1110
pubmed: 30671927
J Thorac Oncol. 2016 Jan;11(1):39-51
pubmed: 26762738
Nat Rev Cancer. 2003 Jun;3(6):422-33
pubmed: 12778132
Chest. 2012 Jul;142(1):151-158
pubmed: 22302300
Front Oncol. 2020 Mar 11;10:324
pubmed: 32219066
J Thorac Dis. 2020 Sep;12(9):4991-5019
pubmed: 33145073
J Immunother Cancer. 2022 Jan;10(2):
pubmed: 35140113
Cancer Cell Int. 2022 Mar 17;22(1):122
pubmed: 35300689
Cancer Discov. 2015 Sep;5(9):932-43
pubmed: 26269515
Oncoimmunology. 2019 Apr 13;8(7):1596004
pubmed: 31143517
J Cancer Res Clin Oncol. 2022 Dec;148(12):3437-3447
pubmed: 35779107
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
Am J Respir Crit Care Med. 2016 Jan 15;193(2):116-30
pubmed: 26583808
Adv Drug Deliv Rev. 2016 Apr 1;99(Pt B):186-196
pubmed: 26278673
Mol Cells. 2021 May 31;44(5):292-300
pubmed: 33972474
Cancer Med. 2019 Dec;8(17):7207-7218
pubmed: 31605439
Front Oncol. 2020 Feb 25;10:188
pubmed: 32161718
Nature. 2011 Jun 08;475(7355):222-5
pubmed: 21654748
Am J Respir Crit Care Med. 2012 May 1;185(9):1004-14
pubmed: 22550210
Nat Rev Cancer. 2001 Oct;1(1):46-54
pubmed: 11900251
Nature. 2021 Jul;595(7868):578-584
pubmed: 34135508
J Thorac Oncol. 2015 Sep;10(9):1240-1242
pubmed: 26291007
Am J Respir Crit Care Med. 2005 Jan 15;171(2):98-102
pubmed: 15557133
J Pathol. 2017 Feb;241(3):313-315
pubmed: 27753093

Auteurs

Yosuke Kagawa (Y)

Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan.
Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

Tokiko Nakai (T)

Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan.

Tetsuro Taki (T)

Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan.

Hiroko Hashimoto (H)

Division of Innovative Pathology and Laboratory Medicine, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan.

Yu Tanaka (Y)

Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan.
Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

Tetsuya Sakai (T)

Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

Yuji Shibata (Y)

Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

Hiroki Izumi (H)

Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

Kaname Nosaki (K)

Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

Hibiki Udagawa (H)

Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

Yoshitaka Zenke (Y)

Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

Shingo Matsumoto (S)

Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

Kiyotaka Yoh (K)

Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

Saori Miyazaki (S)

Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan.

Reiko Watanabe (R)

Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan.

Motohiro Kojima (M)

Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan.
Division of Pathology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan.

Shingo Sakashita (S)

Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan.
Division of Pathology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan.

Naoya Sakamoto (N)

Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan.
Division of Pathology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan.

Masahiro Tsuboi (M)

Department of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Japan.

Koichi Goto (K)

Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

Genichiro Ishii (G)

Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan.
Division of Innovative Pathology and Laboratory Medicine, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH